top of page

ADVISORY BOARD

Strategic and Business Advisors:

 

  • Joe Belanoff, M.D.

    • CEO - Corcept Therapeutics

 

  • Perry Fell, Ph.D.

    • President and CEO – NanoString Technologies, Inc.

    • President and CEO – Seattle Genetics

    • Director, Molecular Immunology – Bristol-Myers Squibb

 

  • Stephen Hilbert, M.B.A.

    • Principal - The Rainier Group

    • Vice President - JP Morgan Asset Management

 

  • Alan Leong, Ph.D., M.S.E.

    • Director of Research - Biotech Stock Research

    • Director - University of Washington Center for Commercialization

 

  • Randall Schatzman, Ph.D.

    • CEO - Alder Biopharmaceuticals

 

  • Douglas Sanders, M.B.A.

    • CFO - CMC Biologics A/S

    • CFO and Head of Business Operations – Hoffmann-La Roche, Roche Consumer Health Division

    • CFO – MediQuest Therapeutics

Collaborators:

 

  • Caltech - Baltimore Lab

  • Seattle BioMed - HIV Vaccines Lab

  • HuMurine

  • Fred Hutchinson Cancer Research Center - Cellular Therapy Laboratory

  • The Jackson Laboratory

 

Clinical and Regulatory Team:

 

  • Richard Chin, M.D.

    • CEO - OneWorld Health

    • CEO - Oxigene

    • Head of Clinical Research - Genentech Biotherapeutics Unit

    • Author of four books on clinical trials

 

  • Allene Dodge

    • VP of Regulatory Affairs and Quality Assurance – Cell Therapeutics

    • Sr. Dir. of Regulatory Affairs and Quality Assurance – CV Therapeutics

    • Director of Regulatory Affairs – Genentech

 

  • Daniel F. Hoth, M.D.

    • Director – Seattle Genetics

    • Chief Medical Officer – Axys

    • Chief Medical Officer – Gensys

    • Director of AIDS Division – NIAID

    • Chief of the Investigational Drug Branch - NCI

 

  • Donna Matuizek

    • Sr. Regulatory Affairs Consultant – Harris Group

    • Sr. Manager of Contract Manufacturing – Dendreon

    • Director of Quality Control – Dendreon

 

  • Rick Stead, M.D.

    • VP of Clinical Research – Immunex

    • Medical Director – Amgen

    • Had significant roles in the clinical development, FDA approval, and commercialization of Epogen® and Neupogen®

 

  • Joyce Frey-Vasconcells, Ph.D.

    • Cell and Gene Therapy Regulatory Consultant – Frey-Vasconcells Consulting

    • Deputy Director Office of Cellular, Tissue, and Gene Therapies  – FDA

    • PharmNet Consulting

Scientific Advisors:

 

  • François-Loïc Cosset, Ph.D.

    • Research Director, CNRS – Viral Envelopes & Retrovirus Engineering – Ecole Normale Supérieure (ENS) de Lyon

    • Developed the novel lentiviral vector needed to transfect B lymphocytes

 

  • Iqbal Grewal, Ph.D., D.Sc., FRCPath (Pre-clinical Advisor)

    • VP of Pre-clinical Development – Seattle Genetics

    • Senior Scientist, Lab Head and Project Leader – Genentech

    • Has brought more than 6 molecules to clinical development.

 

  • Shelly Heimfeld, Ph.D.

    • Scientific Director for Cellular Therapy - Seattle Cancer Care Alliance

    • Lab Director - Fred Hutchinson Cancer Research Center

 

  • Hans-Peter Kiem, M.D.

    • José Carreras/E. Donnall Thomas Endowed Chair for Cancer Research - Fred Hutchinson Cancer Research Center

    • Member - Clinical Research Division, Fred Hutchinson Cancer Research Center

    • Professor of Medicine - University of Washington School of Medicine

 

  • Xin M. Luo, Ph.D.

    • Lead Researcher – Baltimore Lab, Caltech

    • Developed systems for engineering immunity against HIV-1.

    • Studies molecular control mechanisms of B-cell development.

 

  • Cliona Rooney, Ph.D.

    • Investigator – clinical trial for the iCasp9 suicide gene system

    • Expert in cellular immunotherapy

bottom of page